Robert Alexander, MD

Chief scientific officer at the Banner Alzheimer’s Institute.

Articles by Robert Alexander, MD

NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease

ByRobert Alexander, MD,Isabella Ciccone, MPH

December 3rd 2025

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Robert Alexander, MD

Articles by Robert Alexander, MD

NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease

Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug

Alzheimer Trial PRImus-AD Tests Orally Available PRI-002 as New Treatment

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation